Scarica l'app Stockscreener
4.04
10.68%
0.39
Pre-mercato:
3.98
-0.06
-1.49%
Precedente Chiudi:
$3.65
Aprire:
$3.96
Volume 24 ore:
3.60M
Relative Volume:
1.22
Capitalizzazione di mercato:
$658.76M
Reddito:
$296.15M
Utile/perdita netta:
$24.02M
Rapporto P/E:
33.50
EPS:
0.1206
Flusso di cassa netto:
$127.01M
1 W Prestazione:
+16.76%
1M Prestazione:
+19.88%
6M Prestazione:
+172.97%
1 anno Prestazione:
+523.55%
Intervallo 1D:
$3.9507
$4.305
Intervallo di 1 settimana:
$3.41
$4.305
Portata 52W:
$0.5271
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Nome
Ironwood Pharmaceuticals Inc
Settore
Telefono
617-621-7722
Indirizzo
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
4.04 | 591.90M | 296.15M | 24.02M | 127.01M | 0.1206 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | Downgrade | Jefferies | Buy → Hold |
| 2025-04-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | Iniziato | Leerink Partners | Market Perform |
| 2024-08-08 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Iniziato | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Wells Fargo | Overweight |
| 2023-11-09 | Iniziato | Jefferies | Buy |
| 2023-09-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-02 | Iniziato | CapitalOne | Overweight |
| 2022-04-22 | Iniziato | Piper Sandler | Overweight |
| 2020-09-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Iniziato | Northland Capital | Outperform |
| 2019-07-10 | Ripresa | Credit Suisse | Neutral |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Iniziato | H.C. Wainwright | Sell |
| 2018-05-09 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Downgrade | Mizuho | Buy → Neutral |
| 2017-07-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Iniziato | Wells Fargo | Outperform |
| 2017-04-07 | Reiterato | Mizuho | Buy |
| 2017-02-22 | Reiterato | Barclays | Equal Weight |
| 2016-11-04 | Reiterato | Mizuho | Buy |
| 2016-10-24 | Reiterato | Wedbush | Neutral |
| 2016-10-10 | Reiterato | Mizuho | Buy |
| 2016-09-27 | Reiterato | WallachBeth | Hold |
Mostra tutto
Ironwood Pharmaceuticals Inc Borsa (IRWD) Ultime notizie
Ironwood (IRWD) is one of the most attractive small-cap drug manufacturers, here is why - MSN
New Highs: Is Ironwood Pharmaceuticals Inc affected by consumer sentimentM&A Rumor & Consistent Profit Alerts - baoquankhu1.vn
IRWD News | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
Ironwood Pharmaceuticals (IRWD) price target increased by 10.31% to 5.46 - MSN
Breakout Move: Will Ironwood Pharmaceuticals Inc outperform the market in YEAR2026 Chart Watch & Intraday High Probability Setup Alerts - baoquankhu1.vn
Support Test: Does Ironwood Pharmaceuticals Inc have consistent dividend growth2026 EndofMonth & High Win Rate Trade Tips - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Down 5.8%Time to Sell? - MarketBeat
Ironwood (IRWD) is One of the Most Attractive Small-Cap Drug Manufacturers, Here is Why - Insider Monkey
Range Financial Group LLC Acquires Shares of 426,095 Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 5.4%Still a Buy? - MarketBeat
IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock? - TradingView
IRWD (Ironwood Pharmaceuticals) Net Income (Discontinued Op - GuruFocus
IRWD (Ironwood Pharmaceuticals) Inventories, Raw Materials & Components : $0.0 Mil (As of Dec. 2025) - GuruFocus
Aug Update: Can Ironwood Pharmaceuticals Inc outperform in the next rallyMarket Performance Recap & Technical Analysis for Trade Confirmation - baoquankhu1.vn
The Vanguard Group (NASDAQ: IRWD) reports zero beneficial ownership after realignment - Stock Titan
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Ironwood Pharmaceuticals (IRWD) Tops Small-Cap Growth List - GuruFocus
IRWD Stock Price, Quote & Chart | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
Sarissa Capital Management LP Reduces Stake in Ironwood Pharmace - GuruFocus
Ironwood Pharmaceuticals | 10-K: FY2025 Annual Report - Moomoo
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 9%Time to Buy? - marketbeat.com
Gastroparesis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma - Barchart
Will Linzess continue to aid IRWD's top line in 2026 after a soft Q4? - MSN
Market Pulse: Is Ironwood Pharmaceuticals Inc forming a breakout patternCEO Change & Scalable Portfolio Growth Methods - baoquankhu1.vn
Craig-Hallum Sticks to Its Buy Rating for Ironwood Pharma (IRWD) - The Globe and Mail
Sarissa Capital (IRWD) cuts Ironwood stake with 6.7M-share sale, keeps 5.8% - Stock Titan
Aug Rallies: Is Ironwood Pharmaceuticals Inc affected by consumer sentiment2026 Trade Ideas & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Pullback Watch: How much upside does Ironwood Pharmaceuticals Inc have2026 Intraday Action & Weekly High Return Stock Forecasts - baoquankhu1.vn
Insider Selling: Ironwood Pharmaceuticals (NASDAQ:IRWD) Director Sells 6,730,800 Shares of Stock - MarketBeat
Ironwood Pharmaceuticals director Denner sells $20.5m in shares By Investing.com - Investing.com Canada
Ironwood Pharmaceuticals director Denner sells $20.5m in shares - Investing.com
Sarissa funds trim Ironwood (NASDAQ: IRWD) stake with 6.7M-share sale - Stock Titan
Breakouts Watch: Is Ironwood Pharmaceuticals Incs growth already priced in2026 Stock Rankings & Daily Stock Trend Reports - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Short Interest Up 15.8% in February - MarketBeat
Trade Report: Can Ironwood Pharmaceuticals Inc outperform in the next rallyWeekly Trade Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Ironwood hits 52-week high as AbbVie-partnered Linzess boosts 2026 outlook - MSN
Ironwood Pharmaceuticals (IRWD) CLO receives 136,612-share RSU grant - Stock Titan
Ironwood Pharmaceuticals (IRWD) CFO receives 136,612-share stock grant - Stock Titan
Ironwood (NASDAQ: IRWD) CCO granted 136,612 restricted shares as equity award - Stock Titan
Ironwood (IRWD) SVP and CMO awarded 136,612-share RSU performance grant - Stock Titan
Ironwood (IRWD) accounting chief granted 163,934 RSUs in stock award - Stock Titan
Ironwood (NASDAQ: IRWD) CEO receives 409,836-share restricted stock award - Stock Titan
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy? - TradingView
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD) - The Globe and Mail
Ironwood Pharma Maintains Revolving Credit Facility to 2028 - The Globe and Mail
Ironwood Pharmaceuticals Inc Azioni (IRWD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ironwood Pharmaceuticals Inc Azioni (IRWD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| John Minardo | Chief Legal Officer |
Feb 24 '26 |
Sale |
3.66 |
19,053 |
69,734 |
363,886 |
| John Minardo | Chief Legal Officer |
Feb 23 '26 |
Sale |
3.81 |
17,439 |
66,443 |
382,939 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug |
Feb 23 '26 |
Sale |
3.81 |
15,570 |
59,322 |
538,437 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,239 |
41,135 |
213,738 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 23 '26 |
Sale |
3.81 |
10,287 |
39,193 |
224,977 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 24 '26 |
Sale |
3.66 |
103,526 |
378,905 |
1,489,002 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 23 '26 |
Sale |
3.81 |
94,757 |
361,024 |
1,592,528 |
| Martini Gregory S. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,457 |
41,933 |
160,601 |
| Martini Gregory S. | Chief Financial Officer |
Feb 23 '26 |
Sale |
3.81 |
10,487 |
39,955 |
172,058 |
| Silver Ronald | Principal Accounting Officer |
Feb 24 '26 |
Sale |
3.66 |
12,621 |
46,193 |
252,636 |
1.06%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):